Literature DB >> 11889057

Combination therapy for hepatitis B.

A M Di Bisceglie1.   

Abstract

Hepatitis B virus is a major cause of morbidity and mortality worldwide. Effective therapies were first introduced in the mid-1980s but frequent and sometimes severe side effects limit their use. Combination therapy represents the future of treatment for chronic hepatitis B, probably consisting of two or more nucleoside analogues although interferon may form part of some combinations. New drugs acting by different antiviral mechanisms may be particularly potent in combination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889057      PMCID: PMC1773159          DOI: 10.1136/gut.50.4.443

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

2.  Clinical implications of lamivudine resistance by HBV.

Authors:  S W Schalm
Journal:  Lancet       Date:  1997-01-04       Impact factor: 79.321

3.  Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers.

Authors:  J Bissett; M Eisenberg; P Gregory; W S Robinson; T C Merigan
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Authors:  S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 5.  Animal models of hepadnavirus-associated hepatocellular carcinoma.

Authors:  B C Tennant
Journal:  Clin Liver Dis       Date:  2001-02       Impact factor: 6.126

6.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

Authors:  G K Lau; M Tsiang; J Hou; S Yuen; W F Carman; L Zhang; C S Gibbs; S Lam
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

8.  Antiviral L-nucleosides specific for hepatitis B virus infection.

Authors:  M L Bryant; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; P Marion; E Cretton-Scott; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

10.  Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication.

Authors:  B E Korba; J L Gerin
Journal:  Antiviral Res       Date:  1992-07-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.